Haupt Sue, di Agostino Silvia, Mizrahi Inbal, Alsheich-Bartok Osnat, Voorhoeve Mathijs, Damalas Alex, Blandino Giovanni, Haupt Ygal
Research Division, The Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Cancer Res. 2009 Jun 1;69(11):4818-26. doi: 10.1158/0008-5472.CAN-08-4010.
Mutations in the p53 tumor suppressor are the most common genetic events in human cancer. These mutations not only result in a loss of wild-type p53 activity, but can also lead to a gain of new oncogenic properties. Understanding how these gained functions are regulated is in its infancy. In this study, we show that the promyelocytic leukemia (PML) protein is an important regulator of mutant p53. We show that PML interacts with mutant p53. Importantly, PML enhances the transcriptional activity of mutant p53. Unexpectedly, PML is required for the proliferation and colony formation of cancer cells bearing mutant p53. Down-regulation of PML expression inhibits the growth of mutant p53-expressing cancer cells, predominantly by promoting cell cycle arrest. Our results suggest that the tumor suppression function of PML depends on the status of p53. In the context of mutant p53, PML enhances its cancer-promoting activities.
p53肿瘤抑制基因的突变是人类癌症中最常见的基因事件。这些突变不仅导致野生型p53活性丧失,还可能导致新的致癌特性的获得。目前对于这些获得性功能如何被调控的了解尚处于起步阶段。在本研究中,我们表明早幼粒细胞白血病(PML)蛋白是突变型p53的重要调节因子。我们发现PML与突变型p53相互作用。重要的是,PML增强了突变型p53的转录活性。出乎意料的是,PML是携带突变型p53的癌细胞增殖和集落形成所必需的。PML表达的下调抑制了表达突变型p53的癌细胞的生长,主要是通过促进细胞周期停滞实现的。我们的结果表明,PML的肿瘤抑制功能取决于p53的状态。在突变型p53的情况下,PML增强了其促癌活性。